key: cord-0789500-xv58x8ff
authors: Volk, Andreas; Covini-Souris, Caroline; Kuehnel, Denis; De Mey, Christian; Römisch, Jürgen; Schmidt, Torben
title: SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-derived Immunoglobulin
date: 2021-09-17
journal: bioRxiv
DOI: 10.1101/2021.08.13.456066
sha: 449b177d9cc9bfe6c64b68f9eeff477b72f17c7c
doc_id: 789500
cord_uid: xv58x8ff

Introduction Patients suffering from primary or secondary immunodeficiency (PID or SID) face times of increased insecurity and discomfort in the light of the raging COVID-19 pandemic, not knowing if and to what extent their comorbidities impact the course of a potential SARS-CoV-2 infection. Furthermore, recently available vaccination options might not be amenable or effective for all patients of this heterogeneous population. Therefore, these patients often rely on passive immunization with plasma-derived, intravenous or subcutaneous immunoglobulin (IVIG/SCIG). Whether the ongoing COVID-19 pandemic and/or the progress in vaccination programs lead to increased and potentially protective titers in plasma-derived immunoglobulins (Ig) indicated, e.g., for humoral immunodeficiency remains a pressing question for this patient population. Purpose We investigated SARS-CoV-2 reactivity of US plasma-derived IVIG/SCIG products from the end of 2020 until 06/2021 as well as in convalescent plasma (CP) from 05/2020 to 08/2020 to determine whether potentially neutralizing antibody titers may be present. Methods Final containers of IVIG/SCIG and CP donations were analyzed by commercial ELISA for anti-SARS-CoV-2 S1-receptor binding domain (RBD) IgG as well as microneutralization assay using a patient-derived SARS-CoV-2 (D614G) isolate. Neutralization capacities of 313 plasma single donations and 119 plasma-derived IVIG/SCIG lots were determined. Results obtained from both analytical methods were normalized against the WHO International Standard. Finally, based on dense pharmacokinetic (PK) profiles of an IVIG preparation from previously published investigations, possible steady-state plasma levels of SARS-CoV-2 neutralization capacities were approximated based on currently measured anti-SARS-CoV-2 potencies in IVIG/SCIG preparations. Results CP donations presented with a high variability with regards to anti-SARS-CoV-2 reactivity in ELISA as well as in neutralization testing. While approximately 50% of convalescent donations were none/low neutralizing, approximately 10% were at or above 1000 IU/mL. IVIG/SCIG lots derived from pre-pandemic plasma donations did not show neutralizing capacities of SARS-CoV-2. Lots produced between 12/2020 and 06/2021, entailing plasma donations after the emergence of SARS-CoV-2 showed a rapid and constant increase in anti-SARS-CoV-2 reactivity and neutralization capacity over time. While lot-to-lot variability was substantial, neutralization capacity increased from a mean of 20 IU/mL in 12/2020 to 505 IU/mL in 06/2021 with a maximum of 864 IU/mL for the most recent lots. Pharmacokinetic extrapolations, based on non-compartmental superposition principles using steady-state reference profiles from previously published PK investigations on IVIG in PID, yielded potential steady-state trough plasma levels of 16 IU/mL of neutralizing SARS-CoV-2 IgG based on the average final container concentration from 05/2021 of 216 IU/mL. Maximum extrapolated trough levels could reach 64 IU/mL based on the latest maximal final container potency tested in 06/2021. Conclusions SARS-CoV-2 reactivity and neutralization capacity in IVIG/SCIG produced from US plasma rapidly and in part exponentially increased in the first half of 2021. The observed increase of final container potencies is likely trailing the serological status of the US donor population in terms of COVID-19 convalescence and vaccination by at least 5 months due to production lead times and should in principle continue at least until fall 2021. In summary, the data support rapidly increasing levels of anti-SARS-CoV-2 antibodies in IVIG/SCIG products implicating that a certain level of protection could be possible against COVID-19 for regularly substituted PID/SID patients. Nevertheless, more research is still needed to confirm which plasma levels are needed to provide protection against SARS-CoV-2 infection in immune-compromised patients. Plain Language Summary People with deficiencies in their immune system often have an insufficient antibody response to antigens, e.g., bacteria, viruses, or vaccines. These patients therefore often receive antibodies from healthy people to replace the missing antibodies and build a first line of defense against infections. These antibodies (also called immunoglobulins (Ig)) are prepared from plasma of healthy donors, the liquid fraction of the blood without cells. This plasma is then split up in pharmaceutical production into its protein components. One of these is immunoglobulin G (IgG), which is the protein family that neutralizes/inactivates infectious agents as well as marks these infectious agents so they can be recognized by other parts of the immune system. With the ongoing COVID-19 pandemic and the severe to fatal outcomes for certain patient groups, especially people with impaired immunity, these patients and their physicians are interested in whether their antibody replacement therapy also confers protection against SARS-CoV-2 infection. We analyzed the capability of plasma-derived Ig lots to (i) recognize SARS-CoV-2 protein by ELISA method as well as (ii) neutralize SARS-CoV-2 by neutralization studies using the actual virus under biosafety level 3 (BSL-3) conditions. Here we show increasing anti-SARS-CoV-2 activity over time of manufactured Ig lots produced between 12/2020 and 06/2021. The most recent lots had a neutralizing activity of up to 864 IU/mL. Considering that the USA represents Octapharma’s main plasma source, the progress in vaccination levels together with the evolution of the COVID-19 pandemic in this country suggests that the IVIG/SCIG neutralization capacities against SARS-CoV-2 might still increase and could potentially meet a level where antibody plasma concentrations in the patient confer immune protection. Key Points Patients with humoral immunodeficiency rely on plasma-derived immunoglobulin for passive immunization against numerous pathogens. SARS-CoV-2 neutralization capacities of plasma-derived immunoglobulins have increased over time with the ongoing COVID-19 pandemic and vaccination campaigns. Plasma-derived immunoglobulin in prophylactic use for immunodeficient patients could potentially protect against SARS-CoV-2 infection in the future.

To obtain an impression on how CP donations vary in terms of potency, we first investigated a selection of 7 COVID-19 CP donations from 05/2020 to 08/2020 for SARS-CoV-2 reactivity by use of commercially available 8 anti-SARS-CoV-2 IgG ELISA and an inhouse established SARS-CoV-2 microneutralization assay under 9 biosafety level 3 (BSL-3) conditions to assess the actual neutralization capacity. 16 .5 % IgG preparations were tested in 3 dilution series ranging from 1:1 to 1:10. All samples were tested in 8 23 replicates. Results were initially obtained in relative units (RU/mL) and were normalized against the First WHO

International Standard (NIBSC code: 20/136) in binding antibody units/mL (BAU/mL) as described by the test kit 9 2.4. Cell Culture 1 Vero cells (CCL-81, American Type Culture Collection) were cultured in RPMI-1640 medium (Sigma ® ), 2 supplemented with 10% fetal bovine serum (Sigma ® ) and 1% penicillin/streptomycin (Sigma ® ) at 37°C, 5% CO2 3 in saturated humidity.

FRhK-4 cells (CRL-1688, American Type Culture Collection) were cultured in EMEM medium (Sigma ® ) 5 supplemented with 14% RPMI-1640 (Sigma ® ), 5% fetal bovine serum and 1% penicillin/streptomycin (Sigma ® ) 6 at 37°C, 5% CO2 in saturated humidity. 

The internal neutralization standard "V" was generated in-house at Octapharma Virus and Prion Validation by 6 pooling a selection of CP samples. After pooling, samples were aliquoted and kept frozen at -80°C until use.

Standard was diluted 1:40 initial dilution in 20% citrate dextrose (ACD, Sigma ® ) in Vero culture medium to avoid 8 clotting.

The internal neutralization standard "O" was a high-titer, single source plasma donation obtained from Octapharma 10 Plasma Inc., Charlotte, NC, USA. After thawing, the donation was aliquoted and kept frozen at 11 -80°C until use. Standard was diluted 1:40 initial dilution in 20% ACD in Vero culture medium to avoid clotting.

Neutralization testing (NT) was done in two microneutralization assay formats differing in sample dilution 15 schemes and replicates. Both assays were not prospectively validated. In both, Vero cultures were prepared one 16 day prior to assay conduct and 120 µl was seeded in each of the 96 wells with 0.5x10 4 cells/mL (= 600 cells per 17 well).

In the screening assay format, which was used in the CP donation testing, each plasma sample was thawed at 37°C 19 and initially diluted 1:40 with 20% ACD in cell culture medium to avoid clotting. Subsequently, samples were 20 serially diluted 1:2-fold in six consecutive steps. Each of the four parallel dilutions was assayed once for 21 neutralization. The assay principle was adapted from Gauger & Vincent [37].

In the potency assay format deployed for final container testing, each sample was assayed in 3 independent dilution 23 series. After an initial 1:10 dilution step, 10 consecutive 1:2 dilution steps were performed. Each dilution was 24 assayed in octuplicates, respectively. This assay format has been previously published [30, 38] . It shows more 25 reliable results per sample, although throughput is limited and is also restricted owing to BSL-3 procedures.

Experimental performance of both screening and potency assay formats are summarized in Supp. Fig. 1 .

In both assay versions, each sample dilution was subsequently challenged with an equal volume of SARS-CoV-2 28 suspension, which had a titer of 3.0 log10 TCID50/mL. The virus titer was confirmed in each experiment run by so-called back titrations (refer to section "virus titration"). A mean titer of n=5 titrations was determined to 1 accurately account for the actual viral load in the immune neutralization, which was used as a normalizing factor In both formats, the neutralization reaction was incubated for 150 ± 15 min at 37°C in a CO2 incubator at saturated 4 humidity. After the incubation period, 100 µl of each replicate dilution was transferred onto a 96-well culture of 5 Vero cells (see above). Inoculated cultures were maintained for 7 days at 37°C, 5% CO2 in saturated humidity. On 6 day 7, cultures were microscopically evaluated for the presence or absence of cytopathic effect by two independent 7 operators (four eyes-principle). Neutralization potency by means of dilution to achieve a 50% neutralization of assuming that the baseline levels were residuals from previous dosing whilst endogenous levels were negligible.

To be able to pool the profiles across subjects, the baseline-adjusted profiles were dose-normalized. The time were used as reference profiles. These reference profiles were expanded by linear/log-linear interpolation 1 between sampling points and extrapolation beyond the last quantifiable value by means of the apparent terminal 2 disposition rate constant. Steady-state levels were approximated by building time-staggered superposition 3 cascades of the reference profiles for ten 4-weekly doses, assuming the PK to be dose-proportional and time- 

[cumulative] Cases in The United States Reported to CDC" (derived from https://covid.cdc.gov/covid-data-17 tracker/#trends_totalcasescumulative accessed on 12.07.2021). This sum was the divided by the total US 6% of the donations exhibited borderline and negative results, respectively. The antibody ratio ranged from <0.1 6 (limit of detection, LOD) up to 16 while the mean ± standard deviation (SD) ratio was 4.5 ± 3.6 ( Fig. 1a) .

We next set out to investigate what these ELISA data mean in terms of actual virus neutralization. Therefore, 8 313 CP donations including the above sample set were analyzed by actual virus neutralization in a so-called NT 9 screening assay format (Fig. 1b) . We found a high variability of neutralization activity among CP donations.

25% had a neutralization capacity close to or below the LOD (0-45 IU/mL). 28% had only a weak neutralization 11 titer of less than 150 IU/mL. 21% of donations had a mean titer of 223 IU/mL, representing a moderate/average 12 neutralization. 16% had a neutralization titer between 300 IU/mL -600 IU/ml, while only 10% of all donations 

Given the reports on frequent asymptomatic to mild COVID-19 infections and the general interest on how 18 epidemiologic developments (infection as well as vaccination programs) in the US donor population reflects in 19 IVIG/SCIG, we investigated commercial lots derived from US plasma sources for SARS-CoV-2 reactivity from 20 11/2020 until 06/2021 by means of quantitative anti-SARS-CoV-2 S1 RBD IgG ELISA. (Fig. 2a) . Pre-pandemic 21 lots all tested negative in the ELISA, excluding cross-reactivity of the assay against 'common-cold' coronaviruses. Systematic investigations started in 11/2020 and the first reactive lots were detected in 12/2020 23 with ELISA IgG titers ranging from 40 to 170 BAU/mL with a mean value of 100 BAU/mL. A progressive 24 reactivity increase was observed, which took up pace in the very last months of observation. A mean ± SD anti-1 neutralization titer of 21 ± 16 IU/mL). An exponential, yet slow increase in neutralization activities was 2 subsequently observed (i.e., mean values ± SD in 02/2021: 61 ± 37 IU/mL; 04/2021: 107 ± 32 IU/mL; 05/2021: 3 216 ± 96 IU/mL; and 06/2021: 506 ± 242 IU/mL). The maximum NC50 measured was 864 IU/mL. We fitted the 4 median SARS-CoV-2 neutralizing titers by exponential growth equation fit (least squares regression without 5 weighing, no outlier handling and constraints) and found an R² of 0.98. 

were baseline adjusted (Supp. Fig. 2b ) and subsequently normalized to the IVIG dose administered (Supp. Fig.   19 2c). Ultimately, the normalized, baseline adjusted one-dose PK profiles were expanded by staggered 20 superposition to achieve an assumption of a PK time-course of a 4-weekly IVIG treatment regimen (Supp. donors showed a 3.5% seroprevalence in July 2020 [47] .

The observed increase in IVIG/SCIG final container neutralization titers from 02/2021 to 05/2021 (i.e., 61 to 216 of time [30] . Not factored in in this prediction was the successful initial onset of the vaccination campaign in the 23 US. The latter which had an almost exponential increase with regards to "first-dose in" in the total US population 1 the reported exponential increase in serologically relevant exposure of the US total population from the first half-2 year in 2021 (inferring this to be an acceptable correlate of our donor population) suggests a further increase of 3 neutralization capacities at least until fall 2021, while the exponential increase will likely see an inflection point 4 and turn into a saturation phase. At which level SARS-CoV-2 neutralization titers will plateau and how stable 5 this plateau will be over time depends on many factors: e.g., (i) the increase in vaccinees over-taking the CP 6 donors in numbers might potentially lead to a different "on-average", potentially more consistent contribution would correspondingly be about 16 IU/mL (P25: 11 IU/mL, and P75: 16 IU/mL) -provided there are no 5 underlying idiotype-specific elimination processes. The variation found in-between PK profiles is in our opinion 6 less important to an actual antibody plasma trough level (Table 1) , as the actual SARS-CoV-2 neutralization titer 7 in the final container for which we have observed a substantial variation as can be seen in Fig. 2b . Likewise, the 8 spans between the investigated time periods has more impact on the theoretical plasma trough levels than cohorts are needed to provide information on plasma IgG levels in these patients and correlate these with the 10 potencies found in the infused formulations. A further limitation is that the data presented here were generated 11 using the D614G variant close to Wuhan wildtype strain, while the pandemic is currently driven by SARS-CoV-12 2 variants of concern and -interest. Nevertheless, polyclonality of IVIG/SCIG could render a complete 13 neutralization evasion of variants less likely as compared to monoclonal therapies. However, for polyclonal CP 14 (from one donor) immune escape of variants of concern from neutralization has been shown with approximately 15 15x lower neutralization titers, underscoring the general notion that optimal neutralization/protection is achieved 16 against the isolate that caused the immune response [59] . In a passive immunization setting with IVIG/SCIG, 17 this means not only trailing the epidemiology of donors in terms of neutralizing titer but also in terms of quality,

Here, we report the onset of SARS-CoV-2 neutralizing antibodies in IVIG/SCIG final containers from 12/2020 2 with an exponential increase in neutralizing titers. The average values ± SD found were 02/2021: 61 ± 37 3 IU/mL; 04/2021: 107 ± 32 IU/mL; 05/2021: 216 ± 96 IU/mL and 06/2021: 506 ± 242 IU/mL. The maximum 4 NC50 measured so far was 864 IU/mL. Samples are clustered into neutralization potency (NC50) bins (right) and also shown as total sample set (left).

For each ranked sub-population, the mean normalized neutralization titers ± SD are depicted on the left y-axis 

CoV-2 Pandemic on Patients with Primary Immunodeficiency

Immunoglobulins in autoimmunity: history and mechanisms of action

Therapeutic uses of intravenous immunoglobulin (IVIG) in children

Human intravenous immunoglobulin in primary and secondary antibody deficiencies

Cross-neutralization 12 activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins 2020

Estimated US Infection-and Vaccine-18

CoV-2 Seroprevalence Based on Blood Donations

An mRNA Vaccine 21 against SARS-CoV-2 -Preliminary Report

SARS-CoV-2 among infected healthcare workers

IgA dominates the early neutralizing 13 antibody response to SARS-CoV-2

Effective presence of antibodies against common human coronavirus in Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster. medRxiv

Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes

2: PK data processing for superposition analyses. a reference dataset of the observed individual time 2 courses of untransformed IgG-levels on 4-weekly repeated dosing of IVIG

The authors cordially thank Prof. Dr. Christian Drosten, Charité Berlin, Germany, for the provision of virus